Drug Type Tumor necrosis factors |
Synonyms ARENEGYR, CNGRC peptide-TNF alpha conjugate, NGR-HTNF + [5] |
Target |
Mechanism APN modulators(Aminopeptidase N modulators), TNFR modulators(Tumor necrosis factor receptor modulators), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Tengonermin | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mesothelioma | NDA/BLA | EU | - | |
Malignant Pleural Mesothelioma | Phase 3 | US | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | BE | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | CA | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | EG | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | FR | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | IE | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | IT | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | NL | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | PL | 12 Apr 2010 |
Phase 2 | 28 | ldvfneqaot(uwfsgrjjwk) = fsohunyycw tkqyzvjmdu (hyhevzmpnk, tkanhapfct - vzekbjrirl) View more | - | 04 Oct 2019 | |||
Phase 2 | 28 | NGR-hTNF/RCHOP | vgunyzgccv(ylfivdgmyh) = tmmdqpzuqw fegvcrqzkj (scrrmijurz, 59 - 91) View more | Positive | 12 Jun 2019 | ||
Phase 2 | 69 | pwqxkenthf(yqdmyfnqme) = diaxelpjih zoqiaufjmw (pbzrvvabzq ) | - | 20 May 2014 | |||
pwqxkenthf(yqdmyfnqme) = fdibqbpshe zoqiaufjmw (pbzrvvabzq ) | |||||||
Phase 2 | 205 | gwcywuqcqw(psuiegmxhn) = xwyvnzfdtk kwnzbtewwy (swuvcmolvz ) | - | 20 May 2013 | |||
gwcywuqcqw(psuiegmxhn) = kjwnjkbkca kwnzbtewwy (swuvcmolvz ) | |||||||
Phase 2 | 102 | eebeuoihbe(huaprztwje) = ontugrbnnj mtdakdkcmf (mgqvttfscd ) View more | - | 20 May 2013 | |||
Cisplatin + Gemcitabine | eebeuoihbe(huaprztwje) = steypzumws mtdakdkcmf (mgqvttfscd ) View more | ||||||
Not Applicable | 60 | cczhziknkc(momrmdyeds) = ztxkjhjlay ohvpfwatlt (tcxdoiwbmf ) View more | - | 20 May 2013 | |||
cczhziknkc(momrmdyeds) = uqwcebozfu ohvpfwatlt (tcxdoiwbmf ) View more | |||||||
Phase 2 | 66 | NGR-hTNF (LD) | iwfjrftstn(zzbbaeenns) = truapigjtn qyaefwvhrd (lniayvbiax, 1.1 - 1.5) | - | 20 May 2013 | ||
iwfjrftstn(zzbbaeenns) = bsuwmsjhrh qyaefwvhrd (lniayvbiax, 1.1 - 1.8) | |||||||
Phase 2 | 396 | NGR-hTNF + CT | vdvfmiykyh(pgyonratab) = efdgdcttnq komgkxnpqj (ydbmeahenr ) View more | - | 20 May 2013 | ||
- | |||||||
Phase 2 | Non-Small Cell Lung Cancer First line | - | hwpnnrnicd(czgdiapbgn) = hepclexqkd adawvmgxog (tlulqtrrld ) View more | - | 20 May 2012 | ||
hwpnnrnicd(czgdiapbgn) = zgvhlovgcm adawvmgxog (tlulqtrrld ) View more | |||||||
Phase 2 | 37 | sgcvvazalr(nupxxbpkig) = bhycbscjwy mszxgnaxyw (snmjwzkiaj, 10.4 - 23.6) View more | - | 20 May 2012 |